Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-17

Cord blood as an allogeneic source of stem cell for clinical use

Objective


Cord blood cells, collected at birth, have new interesting properties which can be used for treatment of leukemias and other malignant diseases and also for the treatment of genetic or acquired hematological disorders. Cord blood banks have been established worldwide, and thanks to international collaboration, results of allogeneic unrelated cord blood transplants have been analysed. From these studies, it can be concluded that this new source of hematopoietic stem cells is a life-saving therapy used in a large variety of potentially fatal diseases mostly in children. The objectives of this proposal are to better characterise hematopoietic stem cells present in cord blood and take advantage of the immaturity and proliferative characteristics of the cells to treat a large variety of malignant, immunological, genetic and infectious diseases. The proposal will be divided in 4 components: hematopoiesis, immunology, clinical applications of cord blood cells and interface between transplant centres and cord blood banks.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Call for proposal

Data not available

Coordinator

ASSOCIATION POUR LA RECHERCHE SUR LES TRANSPLANTATIONS MEDULLAIRES
EU contribution
No data
Address
Avenue Claude Vellefaux 1
75475 PARIS
France

See on map

Total cost
No data

Participants (10)